PATENT CLAIM ANALYSIS

Application Number: 16068332
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "312000"]

Abstract:
Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.

Claim (Index 7):
The method of  claim 5 , wherein Compound 1 or the pharmaceutically acceptable salt thereof is administered by an interval administration regimen, and the interval administration includes administration periods and rest periods, Wherein the ratio of the administration period to the rest period in days is one of the following ratios: 2:0.5-5, 2:0.5-3, 2:0.5-2, and 2:0.5-1.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 95.0
- Lexical Diversity: 1.41667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12267321', '15533873', '15719636', '11130295', '15315647']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7657216621580517
- 35 USC 102 Novelty (BERT): 0.4653415928476151
- Combined Prediction Score: 0.7356836552270081
- Mean Citation Score: 188.46138
- Max Citation Score: 190.91985
- Similarity Product: 165.73454929554458

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test